About Novo Nordisk
Novo Nordisk is a company based in Bags Sword (Denmark) founded in 1923. It operates as a Direct-to-Consumer (D2C), and Professional Services. Novo Nordisk has raised $145 thousand across 9 funding rounds from investors including European Union and IFU. The company has 76,300 employees as of December 31, 2024. Novo Nordisk has completed 13 acquisitions, including Akero Therapeutics, Biocorp and Calibrium. Novo Nordisk offers products and services including Ozempic, Wegovy, and Cagrilintide. Novo Nordisk operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Bags Sword, Denmark
- Employees 76300 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Novo Nordisk A/S Class B
-
Annual Revenue
$40.45 B (USD)25.03as on Dec 31, 2024
-
Net Profit
$14.07 B (USD)20.68as on Dec 31, 2024
-
EBITDA
$20.61 B (USD)32.83as on Dec 31, 2024
-
Total Equity Funding
$145 K (USD)
in 9 rounds
-
Latest Funding Round
$173.74 K (USD), Grant
Mar 01, 2022
-
Investors
European Union
& 1 more
-
Employee Count
76300
as on Dec 31, 2024
-
Investments & Acquisitions
Akero Therapeutics
& 12 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Novo Nordisk
Novo Nordisk is a publicly listed company on the OMXCOP with ticker symbol NOVO_B in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Novo Nordisk
Novo Nordisk offers a comprehensive portfolio of products and services, including Ozempic, Wegovy, and Cagrilintide. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Ozempic is used for reducing cardiovascular risks effectively.
Wegovy is prescribed for weight loss management purposes.
Cagrilintide is developed for advanced obesity treatment solutions.
Unlock access to complete
Unlock access to complete
Leadership Team
275 people
Software Development Team
233 people
Senior Team
108 people
Product Management Team
58 people
Finance and Accounting
53 people
Human Resources and Administration
53 people
Operations Team
44 people
Data Analysis and Operations Team
42 people
Unlock access to complete
Funding Insights of Novo Nordisk
Novo Nordisk has successfully raised a total of $145K across 9 strategic funding rounds. The most recent funding activity was a Grant round of $173.74 thousand completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Grant — $173,745
-
First Round
First Round
(01 Jun 1984)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2022 | Amount | Grant - Novo Nordisk | Valuation |
investors |
|
| Jan, 2021 | Amount | Grant - Novo Nordisk | Valuation |
investors |
|
| Jan, 2020 | Amount | Grant - Novo Nordisk | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Novo Nordisk
Novo Nordisk has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and IFU. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investment firm
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Novo Nordisk
Novo Nordisk has strategically engaged in corporate development activities, having acquired 13 companies. Notable acquisitions include Akero Therapeutics, Biocorp and Calibrium. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapeutics for metabolic disorders are developed.
|
2017 | ||||
|
Novel therapeutics for metabolic diseases and obesity are developed.
|
2017 | ||||
|
Non-coding RNA therapeutics are developed for cardiovascular disease treatment.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Novo Nordisk
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Novo Nordisk Comparisons
Competitors of Novo Nordisk
Novo Nordisk operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of multiple disorders
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Novo Nordisk
Frequently Asked Questions about Novo Nordisk
When was Novo Nordisk founded?
Novo Nordisk was founded in 1923 and raised its 1st funding round 61 years after it was founded.
Where is Novo Nordisk located?
Novo Nordisk is headquartered in Bags Sword, Denmark.
Who is the current CEO of Novo Nordisk?
Lars Fruergaard Jorgensen is the current CEO of Novo Nordisk.
Is Novo Nordisk a funded company?
Novo Nordisk is a funded company, having raised a total of $145K across 9 funding rounds to date.
How many employees does Novo Nordisk have?
As of Dec 31, 2024, the latest employee count at Novo Nordisk is 76,300.
What is the annual revenue of Novo Nordisk?
Annual revenue of Novo Nordisk is $40.45B as on Dec 31, 2024.
What does Novo Nordisk do?
Novo Nordisk is focused on the development and distribution of pharmaceutical products targeting chronic conditions such as diabetes and obesity. Solutions are provided in various therapeutic areas with an emphasis on innovative treatments. The company operates within the healthcare sector, prioritizing science and technology to address unmet medical needs. Sustainable business practices are integrated into operations, alongside partnerships and a commitment to responsible sourcing. Global procurement strategies are employed to ensure quality and efficiency in supply chains.
Who are the top competitors of Novo Nordisk?
Novo Nordisk's top competitors include Merck, Roivant Sciences and AbbVie.
What products or services does Novo Nordisk offer?
Novo Nordisk offers Ozempic, Wegovy, and Cagrilintide.
Is Novo Nordisk publicly traded?
Yes, Novo Nordisk is publicly traded on OMXCOP under the ticker symbol NOVO_B.
How many acquisitions has Novo Nordisk made?
Novo Nordisk has made 13 acquisitions, including Akero Therapeutics, Biocorp, and Calibrium.
Who are Novo Nordisk's investors?
Novo Nordisk has 2 investors. Key investors include European Union, and IFU.
What is Novo Nordisk's ticker symbol?
The ticker symbol of Novo Nordisk is NOVO_B on OMXCOP.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.